Multiple Sclerosis (MS) – Relapsing remitting multiple sclerosis (RRMS), short-term therapy

(See separate entry for MS)                                                                                              

Recommended Indications in which IG can be used

Order Number: N7-RRMS

RecommendationsIVIG is recommended for short-term therapy in patients with clinically definite relapsing remitting MS, confirmed by a neurologist, and one of the following indications:
  1. Severe relapse of clinically definite RRMS with no response to high-dose methylprednisolone or where methylprednisolone is contraindicated.
  2. Prevention of relapse of clinically definite RRMS where alternative therapies are inappropriate, unavailable, or contraindicated.
Dose/Frequency of AdministrationInduction: 1 to 2 g/kg adjusted body weight divided over 1 to 5 days (maximum 1 g/kg/day).

Maintenance (for indication 2): 0.4 to 1 g/kg adjusted body weight every 4 to 6 weeks.

Once the patient’s condition has stabilized, consider titrating the dose and/or the treatment interval to the lowest dose necessary to maintain clinical effectiveness.